Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLA84 Phase 2 in Healthy Adults 50+
NCT02316470Phase 2Completed
- Sponsor
- Valneva
- Start
- Dec 2014
- Primary completion
- May 2015
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of Clostridium difficile vaccine in Clostridioides difficile infection (CDI) (4 arms), sponsored by Valneva. Primary endpoint: Seroconversion Rate at Day 56. Started Dec 2014; status: completed.
02
Drugs
Clostridium difficile vaccine
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02316470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316470.